Regulation of p53 activity by HIPK2: Molecular mechanisms and therapeutical implications in human cancer cells

Oncogene

Volumn 29, Issue 31, 2010, Pages 4378-4387

  Puca, R ^a,b   Nardinocchi, L ^a,b   Givol, D ^c   D'Orazi, G ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

apoptosis; chemoresistance; HIPK2; p53; post translational modifications; protein conformation

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; LYSINE; PROTEIN P53; SERINE;

ACETYLATION; AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELLULAR STRESS RESPONSE; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENETIC SELECTION; HUMAN; HYPOXIA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SENESCENCE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CARRIER PROTEINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955470408     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.183     Document Type: Review

References (99)

1. Al-Beiti MA, Lu X. (2008). Expression of HIPK2 in cervical cancer: correlation with clinicopathology and prognosis. Aust NZJ Obstet Gynecol, 48 329-336
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
3. Barlev NA, Liu L, Chahab NH, Mansfield K, Harris KG, Halaxonetis TD et al. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferase. Mol Cell 8: 1243-1254.
4. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. (2009). An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucl Acid Res 37: 4587-4602.
5. Bernardi R, Pandolfi PP. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8: 1006-1016.
6. Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
7. Britos-Bray M, Ramirez M, Cao W, Wang X, Liu PP, Civin CI et al. (1998). CBFb-SMMHC, expressed in M4eo acute myeloid leukaemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 92: 4344-4352.
8. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
9. Calzado MA, Renner F, Roscic A, Schmitz ML. (2007). HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 6: 139-143.
10. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML. (2009a). An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. Nat Cell Biol 11: 85-91.
11. Calzado MA, de la Vega L, Munoz E, Schmitz ML. (2009b). Autoregulatory control of the p53 response by Siah-1L-mediated HIPK2 degradation. Biol Chem 390: 1079-1083.
12. Cecchinelli B, Lavra L, Rinaldo C, Iacovelli S, Gurtner A, Gasbarri A et al. (2006). Repression of the anti-apoptotic molecule Galectin-3 by HIPK2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol 26: 4746-4757.
13. Cho YJ, Gorina PD, Jeffrey A, Pavletich NP. (1994). Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
14. Choi DW, Seo YM, Kim EA, Sung KS, Ahn JW, Park SJ et al. (2008). Ubiquitination and degradation of homeodomain-interacting protein kinase-2 by WD40 repeat/SOCS box protein WSB-1. J Biol Chem 283: 4682-4689.
15. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S et al. (2002). Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nat Cell Biol 4: 11-19.
16. D0Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R et al. (2006). Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res 12: 735-741.
17. Dauth I, Kruger J, Hofmann TG. (2007). Homeodomain-interacting protein kinase 2 is the ionizing radiation-activated p53 serine 46 kinase and is regulated by ATM. Cancer Res 67: 2274-2279.
18. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR et al. (2008). High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 27: 4745-4751.
19. Di Lello P, Jenkins LM, Jones TN, Nguyen BD, Hara T, Yamaguchi H et al. (2006). Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell 22: 731-740.
20. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. (2004a). Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 293: 311-320.
21. Di Stefano V, Blandino G, Sacchi A, Soddu S, D'Orazi G. (2004b). HIPK2 neutralizes MDM2 inhibition by rescuing p53 transcriptional activity and apoptotic function. Oncogene 23: 5185-5192.
22. Di Stefano V, Mattiussi M, Sacchi A, D'Orazi G. (2005a). HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett 579: 5473-5480.
23. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. (2005b). HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21WAF1 after nonapoptotic DNA damage. Oncogene 24: 5431-5442.
24. Espinosa JM, Emerson BM. (2001). Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Cell 8: 57-69.
25. Gresko E, Roscic A, Ritterhoff S, Vichalkovski A, Del Sal G, Schmitz ML. (2006). Autoinhibitory control of the p53 response by caspase-mediated processing of HIPK2. EMBO J 25: 1883-1894.
26. Gu W, Roeder RG. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminus domain. Cell 90: 595-606.
27. Hainaut P, Milner J. (1993). A structural role for metal ions in the 'wild-type' conformation of the tumor suppressor protein p53. Cancer Res 53: 1739-1742.
28. Haldar SM, Lu Y, Jeyaraj D, Kawanami D, Cui Y, Eapen SJ et al. (2010). Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Translat Med 2: 1-10.
29. Harris SL, Levine AJ. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
30. Haupt Y, Maya R, Kazaz A, Oren M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299.
31. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, DrogeWet al. (2002). Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 4: 1-10.
32. Isono K, Nemoto K, Li Y, Takada Y, Suzuki R, KatsukiMet al. (2006). Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.Mol Cell Biol 26: 2758-2771.
33. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. (2004). Small molecule RIRA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328.
34. Joenger AC, Fersht AR. (2007). Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26: 2226-2242.
35. Kamata T. (2009). Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100: 1382-1388.
36. Kikuchi A. (1999). Roles of Axin in the Wnt signaling pathways. Cell Signal 11: 777-788. (Pubitemid 29507486)
37. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. (1998). Homeodomaininteracting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 273: 25875-25879.
38. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A et al. (2006). Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173: 533-544.
39. Komiyama S, Taniguchi S, Matsumotot Y, Tsunoda E, Ohto T, Suzuki Y et al. (2004). Potentiality of DNA-dependent protein kinase to phosphorylate Ser46 of human p53. Biochem Biophys Res Commun 323: 816-822.
40. Kondo S, Lu Y, Debbas M, Lin AW, Sarosi I, Itie A et al. (2003). Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci USA 100: 5431-5436.
41. Krieghoff-Henning E, Hofmann TG. (2008). Role of nuclear bodies in apoptosis signalling. Biochem Biophys Acta 1783: 2185-2194.
42. Kubbutat MH, Jones SN, Vousden KH. (1997). Regulation of p53 stability by Mdm2. Nature 387: 299-303.
43. Lanni C, Nardinocchi L, Puca R, Stanga S, Uberti D, Memo M et al. (2010). Homeodomain interacting protein kinase 2: a target for Alzheimer's beta amyloid leading to misfolded p53 and inappropriate cell survival. PLoS ONE 5: e10171.
44. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S et al. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
45. Li Q, Wang X, Wu R, Rui Y, Liu W, Wang J et al. (2007a). Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res 67: 66-74.
46. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S et al. (2007b). Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic sindrome impari AML1-and p53-mediated transcription. Oncogene 26: 7231-7239.
47. Li Q, Lin S, Wang X, Lian G, Lu Z, Guo H et al. (2009). Axin determines cell fate by controlling the p53 activation threshold after DNA damage. Nat Cell Biol 11: 1128-1134.
48. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD et al. (1999). P53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19: 1202-1209.
49. Luo J, Nikolaev AY, Imai S-I, Chen D, Su F, Shiloh A et al. (2001). Negative control of p53 by Sir2a promotes cell survival under stress. Cell 107: 137-148.
50. MacLachlan TK, El-Deiry WS. (2002). Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci USA 99: 9492-94-97.
51. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X et al. (2007). The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosi inhibitor iASPP. Nat Struct Mol Biol 14: 912-920.
52. Marchetti A, Cecchinelli B, D'Angelo M, D'Orazi M, Crescenzi M, Sacchi A et al. (2004). P53 can inhibit cell proliferation through caspase-mediated cleavage of ERK2/MAPK. Cell Death Diff 11: 596-607.
53. Martins CP, Brown-Swigart L, Evans GI. (2006).Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127: 1323-1334.
54. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK et al. (2005). Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280: 25953-25959.
55. Meplan C, Richard M-J, Hainaut P. (2000). Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19: 5227-5236.
56. Moehlenbrink J, Bitomsky N, Hofmann TG. (2010). Hypoxia suppresses chemotherapeutic drug-induced p53 Serine 46 phosphorylation by triggering HIPK2 degradation. Cancer Lett 292: 119-124.
57. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimeczak E, Droge W et al. (2003a). PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 63: 4310-4314.
58. Moller A, Sirma H, Hofmann TG, Staege H, Gresko E, Ludi HS et al. (2003b). Sp100 is important for the stimulatory effect of homeodomain- interacting protein kinase-2 on p53-dependent gene expression. Oncogene 22: 8731-8737.
59. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. (2009). Targeting hypoxia in cancer cells by restoring homeodomain interacting protein kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS ONE 4: e6819.
60. Nardinocchi L, Puca R, Givol D, D'Orazi G. (2010). HIPK2: A therapeutical target to be (re)activated for tumor suppression. Role in p53 activation and HIF-1a inhibition. Cell Cycle 9: 1-6.
61. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
62. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y et al. (2001). P53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 8: 85-94.
63. Peifer M, Polakis P. (2000). Wnt signaling in oncogenesis and embryogenesis\a look outside the nucleus. Science 287: 1606-1609.
64. Pierantoni GM, Bulfone A, Pentimalli F, Fedele M, Iuliano R, Santoro M et al. (2002). The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun 290: 942-947.
65. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S et al. (2007). High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 117: 693-702.
66. Pistritto G, Puca R, Nardinocchi L, Sacchi A, D'Orazi G. (2007). HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ 14: 1837-1839.
67. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E et al. (2008a). Reversible dysfunction of wild-type p53 following homeodomain- interacting protein kinase-2 knockdown. Cancer Res 68: 3707-3714.
68. Puca R, Nardinocchi L, Pistritto G, D'Orazi G. (2008b). Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 109: 403-410.
69. Puca R, Nardinocchi L, Sacchi A, Rechavi G, Givol D, D'Orazi G. (2009a). HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer 8: 85.
70. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D et al. (2009b). Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res 315: 67-75.
71. Puca R, Nardinocchi L, Storace G, Rechavi G, Sacchi A, Givol D et al. (2010). Nox1 is involved with p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Rad Biol Med 48: 1338-1346.
72. Rinaldo C, Prodosmo A, Siepi F, Soddu S. (2007a). HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol 85: 411-418.
73. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F et al. (2007b). MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 25: 739-750.
74. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. (2009). HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs Nutlin-3 and RITA. Cancer Res 69: 6241-6248.
75. Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W et al. (2004). Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 23: 4583-4594.
76. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E et al. (2002). ATM mediates phosphorylation at multiple p53 sites, including Ser46, in response to ionizing radiation. J Biol Chem 277: 12491-12494.
77. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A et al. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841.
78. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K et al. (2010). A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2a. Brain 133: 983-995.
79. Shieh S-Y, Ikeda M, Taya Y, Prives C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 9: 325-334.
80. Shmueli A, Oren M. (2007). Mdm2: p53's lifesaver? Mol Cell 25: 794-796.
81. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. (2007). DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25: 725-738.
82. Tang Y, Luo J, Zhang W, Gu W. (2006). Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839.
83. Tomasini R, Samir AA, Carrier A, Isnardon D, Cecchinelli B, Soddu S et al. (2003). TP53INP1 and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 278: 37722-37729.
84. Unger T, Nau MM, Segal S, Minna JD. (1992). p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11: 1383-1390.
85. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by smallmolecules antagonists of MDM2. Science 303: 844-848.
86. Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK et al. (2001). hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
87. Vazquez A, Bond EE, Levine AJ, Bond L. (2008). The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Disc 7: 979-987.
88. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007). Restoration of p53 function leads to tumor regression in vivo. Nature 445: 661-665.
89. Verhaegh GW, Parat MO, Richard MJ, Hainaut P. (1998). Modulation of p53 conformation and DNA-binding activity by intracellular chelation of zinc. Mol Carcinog 21: 205-214.
90. Vousden KH, Liu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
91. Wang Y, Bedatin K-M, Hug H. (2001). HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. BMC Mol Biol 2: 8-16.
92. Wee H-J, Chih-Cheng Voon D, Bae S-C, Ito Y. (2008). PEBP2-b/CBF-b- dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112: 3777-3787.
93. Wei G, Ku S,Ma GK, Saito S, Tang AA, Zhang J et al. (2007). HIPK2 represses b-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 104: 13040-13045.
94. Wesierska-Gadek J, Schmitz ML, Ranftler C. (2007). Roscovitineactivated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100: 865-874.
95. Wiggins AK, Wei G, Doxakis E, Wong C, Tang AA, Zang K et al. (2004). Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. J Cell Biol 167: 257-267.
96. Winter M, Sombroek D, Dauth I, Moehlenbrink J, Scheuermann K, Crone J et al. (2009). Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10: 812-824.
97. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007). Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
98. Yoshida K, Liu H, Miki Y. (2006). Protein kinase C d regulates Ser46 phoshorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 281: 5734-5740.
99. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S et al. (2002). The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.